{"id":"advair-diskus100-50-g","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Tremor"},{"rate":"5-10","effect":"Headache"},{"rate":"3-5","effect":"Nervousness"},{"rate":"2-5","effect":"Palpitations"},{"rate":"2-5","effect":"Muscle cramps"},{"rate":"5-10","effect":"Oral candidiasis"},{"rate":"3-5","effect":"Dysphonia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluticasone propionate binds to glucocorticoid receptors in the lungs, suppressing inflammatory cytokine production and reducing airway edema and mucus secretion. Salmeterol activates beta-2 adrenergic receptors on airway smooth muscle, causing bronchodilation and prolonging airway patency. Together, these agents provide both anti-inflammatory and bronchodilatory effects for sustained symptom control.","oneSentence":"Advair Diskus combines fluticasone propionate (an inhaled corticosteroid) and salmeterol (a long-acting beta-2 agonist) to reduce airway inflammation and dilate airways in asthma and COPD.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:26:56.268Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance therapy"},{"name":"Chronic obstructive pulmonary disease (COPD) maintenance therapy"}]},"trialDetails":[{"nctId":"NCT03394989","phase":"PHASE3","title":"BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients","status":"COMPLETED","sponsor":"Cipla Ltd.","startDate":"2018-10-17","conditions":"Bronchial Asthma","enrollment":1366},{"nctId":"NCT02649478","phase":"NA","title":"Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2014-08","conditions":"Asthma","enrollment":1430},{"nctId":"NCT01907334","phase":"PHASE4","title":"Dose-Response of Salmeterol in Children","status":"COMPLETED","sponsor":"University of Florida","startDate":"2013-08","conditions":"Asthma","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["fluticasone","salmeterol"],"phase":"marketed","status":"active","brandName":"Advair Diskus100/50 µg","genericName":"Advair Diskus100/50 µg","companyName":"University of Florida","companyId":"university-of-florida","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Advair Diskus combines fluticasone propionate (an inhaled corticosteroid) and salmeterol (a long-acting beta-2 agonist) to reduce airway inflammation and dilate airways in asthma and COPD. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}